Global management consulting and technology services firm ZS has announced a major expansion of ZAIDYN®, its flagship life sciences intelligence platform. Driven by specialized agentic AI, the platform now features two new modular, purpose-built application suites: ZAIDYN Medical™ and ZAIDYN Content™. Purposefully designed to combine deep-seated domain knowledge with data, analytics, and artificial intelligence, such technologies aim to address specific challenges associated with the life sciences sector. This introduction reflects ZS’s dedication to leveraging agentic AI solutions within highly regulated and risky industries where companies can leverage their operations safely.
In turn, ZAIDYN is intended to turn large-scale data into actionable insights in real time without losing any governance aspect and integrating itself seamlessly into an existing work environment. In particular, the platform uses unique digital agents, which monitor operational signals, suggest optimized actions, and manage governed processes while retaining human control over each step of the process. By establishing a shared intelligence infrastructure atop the existing ZAIDYN Commercial suite, the additions of ZAIDYN Medical and ZAIDYN Content aim to give industry leaders the agility to act swiftly, confidently, and uniformly across global divisions.
Also Read: OpenAI Unveils GPT-Rosalind: A Frontier Reasoning Model Tailored for Life Sciences
“ZS has spent decades helping life sciences teams solve their most complex commercial and medical challenges, and now we’re packaging that expertise with agentic AI in our products,” said Sunil Dixit, chief product officer at ZS. “We built these new product lines to address the pressure on life sciences organizations to do more with less. Agents grounded in domain and armed with rich ontologies can support and streamline medical, legal and regulatory (MLR) review workflows and deliver insights to medical affairs teams to help accelerate the speed of their work.”
Introducing ZAIDYN Medical
ZAIDYN Medical builds on ZS’s deep innovation footprint and intellectual property portfolio, which includes multiple granted U.S. patents and pending applications centered on AI-powered medical intelligence. A key component of this suite is ZAIDYN OLI™, which utilizes technology derived from a recently issued U.S. patent, marking a major milestone in ZS’s development of AI-fueled network intelligence for opinion leaders.
The medical affairs applications help teams map out, prioritize, and collaborate with key opinion leaders, cutting the timeline required to generate end-to-end operational insights by 50% to 70%. Additionally, the application suite provides tools designed to identify diagnostic and care gaps, evaluate patient outcomes, synthesize complex scientific discoveries, and maintain compliant medical outreach.
“Medical affairs teams are under increasing pressure to focus their time and attention where it matters most,” said Murali Gopal, MD, senior vice president and head of medical affairs at Ardelyx, Inc. “Approaches that help teams prioritize stakeholders and prepare for scientific engagement more effectively can support more focused conversations and greater continuity across interactions.”
Introducing ZAIDYN Content
ZAIDYN Content delivers a highly adaptable, agentic AI-driven framework focused on speeding up the life sciences content supply chain—from initial asset conceptualization through medical, legal, and regulatory (MLR) approval to localized reuse. Its core module, the Content MLR Accelerator, embeds rigorous compliance mandates, brand standards, and medical insights directly into active editing and review pipelines. This allows creative and scientific teams to optimize submission quality, shorten approval cycles, and safely repurpose content assets without elevating institutional risk.
The suite also facilitates automated content development and localization, empowering businesses to quickly adapt messaging across diverse markets, distinct brands, and multiple languages. Proven at an enterprise level, ZAIDYN Content has already optimized more than 100,000 marketing and educational assets worldwide, reducing the overall turnaround times for tailored derivative content by more than 67%.
“The true value of innovation in life sciences is realized when it reaches the people who need it,” said Jaideep Bajaj, chairman at ZS. “ZAIDYN Content helps organizations deliver important information to patients, providers and stakeholders with greater speed, supporting meaningful impact for all.”
